Compare AbCellera Biologics Inc (ABCL) vs Box Inc (BOX) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
AbCellera Biologics Inc vs Box Inc — how do they compare? AbCellera Biologics Inc trades at $7.19 (market cap $2.35B), while Box Inc trades at $28.99 (market cap $4.00B). The key difference: Box Inc is the larger of the two by market cap, and AbCellera Biologics Inc is trading nearer its 52-week high, Box Inc nearer its low. Which is the better fit depends on your goals.
| ABCL | BOX | |
|---|---|---|
Market Cap | $2.35B | $4.00B |
Sector | Health | Technology |
52-Week High | $8.12 | $33.73 |
52-Week Low | $2.78 | $21.37 |
Enterprise Value | $1.99B | $4.55B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AbCellera Biologics (ABCL) trades at $7.69, down 5.18% today, with a bullish technical signal from moving averages but overbought RSI readings. The company reported a net loss of -$146.41M in 2025, with negative margins, though revenue grew to $75.13M. Recent news highlights a major collaboration with Jazz Pharmaceuticals worth up to $876M, potentially boosting future revenue streams. Analyst consensus is strongly bullish with a $9.67 price target, indicating 25.7% upside.
The outlook hinges on execution of new partnerships and pipeline progress, particularly ABCL635 Phase 2 data expected in Q3 2026. Key risks include persistent cash burn, high valuation multiples despite losses, and biotech sector volatility. Investors should weigh the strong analyst support against fundamental challenges and the stock's current technical overbought condition.
BOX trades at $28.85, up 3.44% today, with a bullish technical signal from moving averages and strong analyst consensus. Revenue grew to $1.09B in 2025, with net income surging to $244.62M, though Q2 2026 EPS is expected at $0.4. The company expanded Box Zones to new regions, enhancing global data governance capabilities.
The outlook is positive with a $37 consensus price target, but risks include high P/E of 44.3 and overbought RSI levels. Earnings growth and strategic expansions present opportunities, yet investor caution is warranted near-term due to valuation and potential volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AbCellera Biologics Inc
AbCellera Biologics Inc is a biotechnology company. It develops antibodies to treat infectious diseases and various other types of diseases. The company's AI-powered technology sources, searches, decodes and analyzes antibody responses to engineer new antibody drug candidates for its partners.
Read more on ABCL →About Box Inc
Box is a cloud-based content services platform that provides cloud-based storage and workflow collaboration services for enterprise customers. The firm was founded in 2005 as a file sync and sharing provider. More recently, however, the company has focused on bolstering its product portfolio by adding tools such as governance and e-signature that enhance workflow management and collaboration.
Read more on BOX →
